The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 7, 2004, Pages 785-792

  Wang, Chuan Yue ^a   Zhang, Zhang Jin ^b   Li, Wen Biao ^a   Zhai, Yi Min ^a   Cai, Zhuo Ji ^a   Weng, Yong Zhen ^a   Zhu, Rong Hua ^c   Zhao, Jing Ping ^c   Zhou, Hong Hao ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c Central South University   (China)

Author keywords

Clozapine; Fluvoxamine; Healthy volunteers; Olanzapine; Pharmacokinetics

Indexed keywords

CLOZAPINE; FLUVOXAMINE; OLANZAPINE;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEADY STATE; TACHYCARDIA;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; BENZODIAZEPINES; CLOZAPINE; DRUG INTERACTIONS; FLUVOXAMINE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE;

EID: 2942635933     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266621     Document Type: Article

References (54)

1. Sonawalla SB, Fava M: Severe depression: is there a best approach? CNS Drugs 2001;15:765-776.
2. Weimer E, Braus DF, Cavus I, Thome J: Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression. Fortschr Neurol Psychiatr 2002;70:210-217.
3. Lammers CH, Deuschle M, Weigmann H, Hartter S, Hiemke C, Heese C, et al: Coadministration of clozapine and fluvoxamine in psychotic patients-clinical experience. Pharmacopsychiatry 1999; 32:76-77.
4. Poyurovsky M, Hermesh H, Weizman A: Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Clin Neuropharmacol 1996;19:305-313.
5. Silver H, Kushnir M, Kaplan A: Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 1996;40:671-674.
6. Silver H: Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 2001;7:283-304.
7. Armstrong SC, Stephans JR: Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. J Clin Psychiatry 1997;58:499.
8. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T: Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 2000;149:163-169.
9. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH: Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61:594-599.
10. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, et al: Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32:148-153.
11. Bogetto F, Bellino S, Vaschetto P, Ziero S: Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000;96:91-98.
12. Marazziti D, Pallanti S: Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999; 156:1834-1835.
13. Potenza MN, Wasylink S, Longhurst JG, Epperson CN, McDougle CJ: Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1998; 18:423-424.
14. Weiss EL, Potenza MN, McDougle CJ, Epperson CN: Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-527.
15. Potenza MN, Wasylink S, Epperson CN, McDougle CJ: Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry 1998;155:1299-1300.
16. Stein MB, Kline NA, Matloff JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159:1777-1779.
17. Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Hartter S, et al: Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002;22:502-506.
18. Perry PJ, Lund BC, Sanger T, Beasley C: Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001;21:14-20.
19. Perucca E, Gatti G, Spina E: Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994;27:175-190.
20. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG, et al: Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000;148:83-89.
21. Dequardo JR, Roberts M: Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996;153:840-841.
22. DuMortier G, Lochu A, Colen de Melo P, Ghribi O, Roche-Rabreau D, DeGrassat K, et al: Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 1996;153:738-739.
23. Gex-Fabry M, Balant-Gorgia AE, Balant LP: Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25:46-53.
24. Heeringa M, Beurskens R, Schouten W, Verduijn MM: Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 1999;21:243-244.
25. Koponen HJ, Leinonen E, Lepola U: Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996;6:69-71.
26. Weigmann H, Gerek S, Zeisig A, Muller M, Hartter S, Hiemke C: Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410-413.
27. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Harter S, et al: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
28. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-1214.
29. Brosen K: Differences in interactions of SSRIs. Int Clin Psychopharmacol 1998;13:S45-S47.
30. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-193.
31. Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, et al: In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) 1999;145:91-98.
32. Desai HD, Seabolt J, Jann MW: Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001;15:469-494.
33. Naranjo CA, Sproule BA, Knoke DM: Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1999;14:S35-S47.
34. Olesen OV, Linnet K: Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000;20:35-42.
35. Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, et al: Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 2001;21:603-607.
36. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J: CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002;22:1001-1006.
37. Li WB, Zhai YM, Wang CY, Weng YZ, Cai ZJ: Measurement of olanzapine in human serum utilizing high-performance liquid chromatography with electrochemical detection. Drug Anal 2000;20:304-307.
38. Zhu R, Wang C, Zhao J, Chen Y, Zhou H: Determination of clozapine and its N-demethylated metabolite in serum by gas chromatography-mass spectrometry with selected ion monitoring. Se Pu 1998;16:317-320.
39. Steinijans VW, Hauschke D: Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990;28: 105-110.
40. Liu CY, Chiu NY, Wu CK, Yuan LM, Hsiao MC, Liao O: Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int Clin Psychopharmacol 2003;18:49-51.
41. Markowitz JS, DeVane CL, Boulton DW, Liston HL, Risch SC: Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. J Clin Pharmacol 2002;42:104-106.
42. Markowitz JS, Devane CL, Liston HL, Boulton DW, Risch SC: The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin Pharmacol Ther 2002;71:30-38.
43. Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR: Ethnicity and antipsychotic response. Ann Pharmacother 1997;31:1360-1369.
44. Ruiz S, Chu P, Sramek J, Rotavu E, Herrera J: Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 1996;63:306-309.
45. Gossen D, de Suray JM, Vandenhende F, Onkelinx C, Gangji D: Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002;4:E11.
46. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L: The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-46.
47. Fischer V, Vogels B, Maurer G, Tynes RE: The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992;260:1355-1360.
48. Jann MW, Grimsley SR, Gray EC, Chang WH: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24: 161-176.
49. Jerling M, Lindstrom L, Bondesson U, Bertilsson L: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-374.
50. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK: Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-990.
51. Hemeryck A, Belpaire FM: Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37.
52. Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, et al: Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25: 81-93.
53. Linnet K: Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 2002;17:233-238.
54. Li M, Zhang ML: Other tricyclic structures, in: Chen YF, Gu NF (eds.), New Revision of Manual of Clinical Psychopharmacology. Jinan, China: Shandong Publishing House of Science and Technology, 1998:30.